Clinical Trial Detail

NCT ID NCT01529827
Title Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Roswell Park Cancer Institute
Indications

hematologic cancer

Therapies

Melphalan

Methotrexate

Tacrolimus

Mycophenolate mofetil

Fludarabine

Age Groups: adult child senior

No variant requirements are available.